A Systematic Review of the Outcomes of Mucosa-Associated Lymphoid Tissue Intracranial Lymphomas

IF 1.6 4区医学 Q3 SURGERY

ANZ Journal of Surgery Pub Date : 2025-08-07 DOI:10.1111/ans.70246

Kate Poulgrain, Kristy Scandrett, Gemma Olsson, Kirsty Hamilton

{"title":"A Systematic Review of the Outcomes of Mucosa-Associated Lymphoid Tissue Intracranial Lymphomas","authors":"Kate Poulgrain, Kristy Scandrett, Gemma Olsson, Kirsty Hamilton","doi":"10.1111/ans.70246","DOIUrl":null,"url":null,"abstract":"<div>\n \n \n <section>\n \n <h3> Background</h3>\n \n <p>Mucosa-associated lymphoid tissue (MALT) lymphoma in the central nervous system (CNS) is rare. As part of the non-Hodgkin B cell lymphoma group, it is much more indolent in presentation and progression than its aggressive cousin diffuse B-cell lymphoma (DBCL) of the CNS.</p>\n </section>\n \n <section>\n \n <h3> Methods</h3>\n \n <p>This systematic review collates all the published outcome and treatment data on CNS MALT to shed more light on this rare entity.</p>\n </section>\n \n <section>\n \n <h3> Results</h3>\n \n <p>With 3-year overall survival rates of over 94%, females represent two thirds of cases. Dural involvement is much more common and carries a positive prognostic advantage, as does younger age. Treatment strategies still appear to be widely varied, but surgery and adjuvant therapy appear to provide the longest lasting progression-free survival.</p>\n </section>\n \n <section>\n \n <h3> Conclusion</h3>\n \n <p>The rare entity of CNS MALT lymphoma can present in a range of ways. While this means a variety of symptoms, its general prognostic course is usually more indolent than other B cell lymphomas. It frequently affects a younger and more female predominant population, yet no demographic, presentation, or histological characteristics are associated with poorer prognosis. Its rare nature means collaborative databases will need to be considered to better collect robust data for quantitative analysis on ideal treatment and prognosis.</p>\n </section>\n </div>","PeriodicalId":8158,"journal":{"name":"ANZ Journal of Surgery","volume":"95 7-8","pages":"1329-1338"},"PeriodicalIF":1.6000,"publicationDate":"2025-08-07","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":null,"platform":"Semanticscholar","paperid":null,"PeriodicalName":"ANZ Journal of Surgery","FirstCategoryId":"3","ListUrlMain":"https://onlinelibrary.wiley.com/doi/10.1111/ans.70246","RegionNum":4,"RegionCategory":"医学","ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"Q3","JCRName":"SURGERY","Score":null,"Total":0}

引用次数: 0

Abstract

Background

Mucosa-associated lymphoid tissue (MALT) lymphoma in the central nervous system (CNS) is rare. As part of the non-Hodgkin B cell lymphoma group, it is much more indolent in presentation and progression than its aggressive cousin diffuse B-cell lymphoma (DBCL) of the CNS.

Methods

This systematic review collates all the published outcome and treatment data on CNS MALT to shed more light on this rare entity.

Results

With 3-year overall survival rates of over 94%, females represent two thirds of cases. Dural involvement is much more common and carries a positive prognostic advantage, as does younger age. Treatment strategies still appear to be widely varied, but surgery and adjuvant therapy appear to provide the longest lasting progression-free survival.

Conclusion

The rare entity of CNS MALT lymphoma can present in a range of ways. While this means a variety of symptoms, its general prognostic course is usually more indolent than other B cell lymphomas. It frequently affects a younger and more female predominant population, yet no demographic, presentation, or histological characteristics are associated with poorer prognosis. Its rare nature means collaborative databases will need to be considered to better collect robust data for quantitative analysis on ideal treatment and prognosis.

查看原文本刊更多论文

颅内粘膜相关淋巴组织淋巴瘤预后的系统综述。

背景：粘膜相关淋巴组织（MALT）淋巴瘤在中枢神经系统（CNS）是罕见的。作为非霍奇金B细胞淋巴瘤组的一部分，它的表现和进展比中枢神经系统的侵袭性弥漫性B细胞淋巴瘤（DBCL）更缓慢。方法：本系统综述整理了所有已发表的中枢神经系统MALT的预后和治疗数据，以更多地了解这种罕见的实体。结果：3年总生存率超过94%，女性占2 / 3。硬脑膜受累更为常见，并且具有积极的预后优势，就像年轻一样。治疗策略似乎仍然多种多样，但手术和辅助治疗似乎提供了最长的持续无进展生存期。结论：罕见的中枢神经系统MALT淋巴瘤有多种表现形式。虽然这意味着多种症状，但其总体预后过程通常比其他B细胞淋巴瘤更为缓慢。它经常影响年轻和更多的女性优势人群，但没有人口统计学、表现或组织学特征与较差的预后相关。它的罕见性质意味着需要考虑协作数据库，以便更好地收集可靠的数据，对理想的治疗和预后进行定量分析。

本文章由计算机程序翻译，如有差异，请以英文原文为准。

求助全文

约1分钟内获得全文求助全文

来源期刊

ANZ Journal of Surgery 医学-外科

CiteScore

2.50

自引率

11.80%

发文量

720

审稿时长

2 months

期刊介绍： ANZ Journal of Surgery is published by Wiley on behalf of the Royal Australasian College of Surgeons to provide a medium for the publication of peer-reviewed original contributions related to clinical practice and/or research in all fields of surgery and related disciplines. It also provides a programme of continuing education for surgeons. All articles are peer-reviewed by at least two researchers expert in the field of the submitted paper.